Plasminogen activator inhibitor type 1 in diabetes and hypertension

W. Reid Litchfield*, Nancy Brown, Douglas E. Vaughan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Plasminogen activator inhibitor type 1 (PAI-1) is the primary inhibitor of tissue plasminogen activator and a crucial element of the endogenous fibrinolytic system. Elevated levels of PAI-1 appear to be associated with an increased incidence of myocardial infarction and increased cardiovascular risk. Strong associations between PAI-1 and hypertriglyceridemia, hyperinsulinemia, and hypertension suggest that part of the increase in cardiovascular risk seen in individuals with these conditions may be related to elevated levels of PAI-1. The increased cardiovascular risk seen in those with essential hypertension may relate to an independent interaction between the renin-angiotensin system and PAI-1. The extent to which PAI-1 explains the increased incidence of cardiovascular disease in diabetic and hypertensive patients, as well as the extent to which this incidence can be reduced, remains unclear.

Original languageEnglish (US)
Pages (from-to)233-238
Number of pages6
JournalCurrent Opinion in Endocrinology and Diabetes
Issue number3
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Plasminogen activator inhibitor type 1 in diabetes and hypertension'. Together they form a unique fingerprint.

Cite this